Perrigo’s Loss Is Lupin’s Gain On Albuterol
As Lupin’s Somerset Site Gets 13 Observations Following FDA Inspection
Executive Summary
Having gained from Perrigo’s US withdrawal of generic ProAir (albuterol sulphate), Lupin plans to ramp up capacity by its financial fourth quarter as demand is seen rising on account of flu and COVID-19 cases in the US. Meanwhile, FDA observations at its Somerset facility provide a dampener.
You may also be interested in...
Lupin Delivers On Generic Fostair With UK Luforbec Launch
Having previously seen patent litigation with originator Chiesi dismissed, Lupin has realized plans to launch the first UK generic version of Fostair (beclometasone/formoterol), with the potential for significant cost savings for the UK’s National Health Service.
Lupin Gets Head Start On Brovana With US Authorized Generic
Lupin has gained a head start on other US generic rivals to Sunovion’s Brovana treatment for COPD with the launch of an authorized generic version of arformoterol tartrate inhalation solution.
Sandoz Shakes Up US Albuterol Market With Proventil Deal
Sandoz has struck a US deal to in-license both branded Proventil HFA and an authorized generic version of the albuterol sulfate product from Kindeva Drug Delivery. The deal comes after a busy year for generic versions of albuterol that have transformed the market dynamics for the respiratory treatment.